



F. No.03-42/2020-QC  
Government of Pakistan  
**Drug Regulatory Authority of Pakistan**  
Ministry of National Health Services,  
Regulation & Coordination  
\*\*\*\*\*

**MOST IMMEDIATE**  
**THROUGH COURRIER**

Islamabad, the 22<sup>nd</sup> October, 2020.

## [Medical Product Alert]

### “Xylop 1% Injection”

M/s. Palpex Pharmaceuticals (Pvt.) Ltd.,  
Plot No. FD 46-A8 St. 1, Sector 38, Korangi Creek,  
**Karachi.**

Subject: **DRUG RECALL OF XYLOP 1% INJECTION BATCH NO. BBH06**  
**MANUFACTURED BY M/S. PALPEX PHARMACEUTICALS (PVT.)**  
**LTD., KARACHI.**

I am directed to refer to the subject cited above and reports of Central Drugs Laboratory, Karachi vide No. R.IP.99/2020 (Initial) wherein Central Drugs Laboratory Karachi has declared subject mentioned batch of Xylop 1% injection present in the combo pack of product “Kanbact 500mg Injection” (manufactured by M/s. Kanel Pharmaceuticals, Islamabad) as “**Adulterated and Sub-Standard**”. Details of CDL reports are as under;

#### **SPECIFICATIONS FOR FINISHED PRODUCT (XYLOP 1% INJECTION)**

<b>S. No.</b>	<b>Test</b>	<b>Specifications</b>	<b>Result</b>	<b>Reference</b>
1.	Description	Sterile solution of Lignocaine Hydrochloride in Water for Injection. Should be free from visible particles.	<b>Colourless solution, containing visible glass particles.</b> <b>Does not comply</b>	BP 2020

02. You are therefore directed to recall all the stocks of mentioned batches of product “Xylop 1% Injection” from market, alert your sales officers/suppliers/ distributors to issue instructions to the pharmacies/hospitals, point of sales/purchase/use for the return of suspected stocks of product in question. Furthermore, you are directed to submit a compliance report of recall to this division within seven (07) days positively.

(Hafiz Sanaullah Babar)  
**Assistant Director QC-III**

**Copy for information and necessary action – with request to issue necessary directions to points of use/sale (Hospitals Pharmacies, Medical stores, Distributors, Whole sellers, etc) under administrative control/ fall under area of jurisdiction, please.**

1. The Secretary (SHC&ME) Health Department (Government of Punjab).
2. The Secretary Primary and Secondary Health Department (Government of Punjab).
3. The Secretary Health Department (Government of Sindh).
4. The Secretary (SHC&ME) Health Department (Government of KPK).
5. The Secretary (SHC&ME) Health Department (Government of Baluchistan).
6. The Secretary (SHC&ME) Health Department (Government of AJ&K).
7. The Director General Health, M/o NHR&C, Islamabad.
8. The Director General Health, Government of Punjab.
9. The Director General Health, Government of Sindh.
10. The Director General Health, Government of KPK.
11. The Director General Health, Government of Baluchistan.
12. The Director General Health, Government of AJ&K.
13. The Additional Director / Office In-charge, DRAP, Lahore, Karachi, Islamabad, Peshawar, and Quetta.
14. The Chief Drug Controller / Inspector Punjab, Sindh, KPK, Baluchistan, AJ&K, GB and ICT.

**Copy to: -**

- i. The Director, QA&LT, DRAP, Islamabad.
- ii. The Additional Director MIS **with request to upload it on official website in the larger interest of public.**
- iii. The Additional Director, DRAP, Karachi.
- iv. Area FID Islamabad for information record and necessary action please.
- v. Area FID Karachi for necessary action please.
- vi. PS to CEO, DRAP, Islamabad.
- vii. Assistant Director QC-I for information and record.
- viii. Office copy.

  
(Assistant Director QC-III)